- Home
- GOVX vs HKPD Comparison
GOVX vs HKPD Comparison
Compare GOVX & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOVX | HKPD |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 10.6M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GOVX | HKPD |
|---|---|---|
| Price | $0.25 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 651.7K | 133.9K |
| Earning Date | 11-13-2025 | 08-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,353,560.00 | ★ $20,313,818.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.52 | ★ 21.72 |
| 52 Week Low | $0.28 | $0.71 |
| 52 Week High | $2.75 | $3.79 |
Technical Indicators
Market Signals| Indicator | GOVX | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 22.60 | 24.76 |
| Support Level | $0.37 | $0.76 |
| Resistance Level | $0.41 | $0.86 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.30 | 0.00 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.